A Single-Centre, Open-label Study Testing the Safety and Performance of the Glyconics-SX System in Individuals With or Without Type 2 Diabetes
A Single-Centre, Open-label Study Testing the Safety and Performance of the Glyconics-SX System in Individuals With or Without Type 2 Diabetes
The main clinical study objective is to retrieve initial high quality spectra measurements indicative of the accuracy of the Glyconics-SX System in distinguishing between individuals with or without T2DM based on known and/or assumed clinical status and as controlled by values of an internal biomarker indicative of glycaemia, HbA1c, as measured with a validated comparator device.
Inclusion Criteria:
Exclusion Criteria:
Individuals with any known medical conditions impacting either of the assessment methodology for glycaemia, such as
anaemia (iron deficiency sickle cell anaemia or similar)
haemoglobinopathies or atypical haemoglobin subtypes not detectable by regular assays,
severe renal impairment (CKD stage III-IV) or decompensated hepatic disease
severe Vitamin D deficiency
known severe immunodeficiency such as HIV, malignancy or other chronic condition significantly impacting assessment of glycaemia
eating disorders (as per clinical assessment)
Recent (within 28 days) blood donation
o Any structural, deviating and visually detectable deviations in the appearance of the nails potentially impacting the spectra measurement, including
nail dystrophy or deformity
severe nail infections (onychomycosis causing visual changes in the appearance of the nail)
rare hereditable conditions impacting the structure of keratin
mechanical damage or marks on the surface of the nail after removal of nail polish
use of acrylic or gel nail decoration and polish, which cannot be removed o Any systemic or topical medication known to modify either the surface or structure of the nail or accuracy of HbA1c value.